CRANBURY, N.J., Sept. 28, 2015 /PRNewswire/ -- Palatin
Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company
developing targeted, receptor-specific peptide therapeutics for the
treatment of diseases with significant unmet medical need and
commercial potential, today announced that a poster entitled
"Conditional cardiomyocyte-restricted Corin KO mice demonstrate
enhanced cardiac hypertrophy and pro-fibrotic gene activation in
response to TAC and PL-3994 – a novel selective GC-A receptor
peptide agonist rescues the phenotype" was presented on
Sunday, September 27, at the 2015
Heart Failure Society of American Annual Meeting in Washington, DC. PL-3994 is a synthetic
natriuretic peptide receptor-A agonist developed by Palatin for
treatment of heart failure and other indications.
The research work was done at Temple
University School of Medicine in Philadelphia under the direction of
Daniel L. Dries, M.D., and
investigated the role of cardiomyocytes, corin and cardiac
natriuretic peptide signaling in heart failure and the potential of
treatment with PL-3994. The data presented demonstrated that corin
and cardiac natriuretic peptides play an important role in
regulating cardiac hypertrophy and fibrosis, and that treatment
with PL-3994 significantly reduced cardiac hypertrophy and
pro-fibrotic and inflammatory gene activation.
Corin is a protease which processes natriuretic peptides from
their inactive form to their active form. About 13% of Black
Americans are heterozygous for a loss-of-function mutation in the
corin gene which can lead to insufficient natriuretic peptide
signaling. The poster presented data utilizing a cardiomyocyte
conditional corin knock-out mouse model developed in Dr. Dries'
laboratory.
The research work was conducted as part of sponsored research
agreement between Temple University
School of Medicine and Palatin Technologies. Daniel L. Dries, M.D. and Bin Xu, Ph.D. from
Temple University School of Medicine
and John Dodd, Ph.D. and
Carl Spana, Ph.D. of Palatin were
among authors on the poster.
PL-3994, which has undergone Phase 1 and Phase 2A safety trials,
is under development by Palatin for heart failure
indications. Contingent on adequate available funds, a
multiple ascending dose Phase 2 study in patients with heart
failure, including patients with corin loss-of-function mutations,
is planned for 2016 to evaluate safety, symptom relief and
pharmacokinetic and pharmacodynamic endpoints.
About Palatin Technologies, Inc.
Palatin
Technologies, Inc. is a biopharmaceutical company developing
targeted, receptor-specific peptide therapeutics for the treatment
of diseases with significant unmet medical need and commercial
potential. Palatin's strategy is to develop products and then form
marketing collaborations with industry leaders in order to maximize
their commercial potential. For additional information
regarding Palatin, please visit Palatin's website at
www.Palatin.com.
Forward-looking Statements
Statements in
this press release that are not historical facts, including
statements about future expectations of Palatin Technologies, Inc.,
such as statements about clinical trial results, potential actions
by regulatory agencies including the FDA, regulatory plans,
development programs, business development and licensing programs,
proposed indications for product candidates and market potential
for product candidates, are "forward-looking statements" within the
meaning of Section 27A of the Securities Act of 1933, Section 21E
of the Securities Exchange Act of 1934 and as that term is defined
in the Private Securities Litigation Reform Act of 1995. Palatin
intends that such forward-looking statements be subject to the safe
harbors created thereby. Such forward-looking statements involve
known and unknown risks, uncertainties and other factors that could
cause Palatin's actual results to be materially different from its
historical results or from any results expressed or implied by such
forward-looking statements. Palatin's actual results may differ
materially from those discussed in the forward-looking statements
for reasons including, but not limited to, results of clinical
trials, regulatory actions by the FDA and the need for regulatory
approvals, Palatin's ability to fund development of its technology
and establish and successfully complete clinical trials, the length
of time and cost required to complete clinical trials and submit
applications for regulatory approvals, entering into marketing and
distribution agreements, products developed by competing
pharmaceutical, biopharmaceutical and biotechnology companies,
commercial acceptance of Palatin's products, and other factors
discussed in Palatin's periodic filings with the Securities and
Exchange Commission. Palatin is not responsible for updating for
events that occur after the date of this press release.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/preclinical-data-on-pl-3994-for-heart-failure-and-resistant-hypertension-presented-at-2015-heart-failure-society-of-america-annual-meeting-300149516.html
SOURCE Palatin Technologies, Inc.